

XtalPi secures \$46M in Series B1 extension

26 October 2018 | News

The new financing will fuel the development of XtalPi's AI applications for critical steps of drug research and development (R&D).



XtalPi Inc., a Boston-Shenzhen computation-driven biotech startup integrating quantum physics, artificial intelligence (AI), and cloud computing to empower pharmaceutical research, has announced a Series B-1 extension financing of \$46 million to support XtalPi's continuous market growth and expand the application of its technology into new areas of pharmaceutical research.

The new investment, led by China Life Healthcare Fund and with participation from SIG and Yael Capital, will add to the original Series B round of \$15 million closed in January 2018 backed by Sequoia China, Google, and Tencent, and bring XtalPi's total fund raised to over \$66 million.

Building on current momentum and success, the new financing will fuel the development of XtalPi's AI applications for critical steps of drug research and development (R&D), with an immediate focus on algorithmic tools that expand the searchable chemical space in drug discovery, achieve accurate predictions of key drug properties, and help further accelerate and optimize later stages of drug development. In addition, XtalPi is poised to upgrade its Intelligent Digital Drug Discovery and Development (ID4) platform with industry-leading cloud computing power and data security in order to offer highly customized solutions to meet the particular needs of pharmaceutical companies.